Introduction and Research Disclaimer
Cagrilintide is a long-acting, investigational amylin analog peptide supplied as a lyophilized powder (10 mg per vial) for use exclusively in controlled laboratory and preclinical research settings. This product is strictly for research use only and is not intended for human consumption, therapeutic application, or diagnostic purposes under any circumstances. Researchers handling Cagrilintide must operate within the bounds of applicable institutional, local, and international regulations governing the use of research peptides. All experimental protocols should be reviewed and approved by the relevant institutional biosafety or animal care and use committees prior to initiation.
Cagrilintide was developed as a long-acting analog of the endogenous peptide hormone amylin, which is co-secreted with insulin from pancreatic beta cells in response to nutrient intake. By leveraging the native amylin signaling axis with enhanced pharmacokinetic properties, Cagrilintide provides a powerful tool for investigating the neuroendocrine regulation of energy homeostasis, gastric emptying, and satiety signaling in preclinical models. The peptide has garnered significant attention in metabolic research following encouraging results from early-phase clinical investigations, making it a valuable reference compound for comparative studies of amylin receptor pharmacology.
All researchers are advised to consult the most current literature and safety data sheets before initiating studies with this compound. Biosim Peptides provides Cagrilintide solely as a research reagent and makes no claims regarding its safety, efficacy, or suitability for any use beyond laboratory investigation.
Molecular Overview
Cagrilintide is a synthetic peptide analog engineered from the 37-amino-acid sequence of human amylin (islet amyloid polypeptide, IAPP). The native amylin peptide is characterized by a conserved N-terminal disulfide bond between cysteine residues at positions 2 and 7, an amphipathic alpha-helical mid-region, and a C-terminal amidation that is essential for full biological activity at the amylin receptor complex. However, native human amylin has poor aqueous solubility and a pronounced propensity to form cytotoxic amyloid fibrils, which limits its utility as a research tool and therapeutic candidate.
To overcome these limitations, Cagrilintide incorporates several key structural modifications. The peptide backbone has been engineered to include amino acid substitutions at positions known to reduce the amyloidogenic potential of the native sequence, improving solubility without compromising receptor binding affinity. Most critically, Cagrilintide is covalently conjugated to a fatty acid moiety via a hydrophilic linker, enabling reversible, high-affinity binding to serum albumin. This albumin-binding strategy substantially prolongs the circulating half-life of the peptide, extending its duration of action to approximately one week following a single administration in pharmacokinetic studies — a marked improvement over the approximately 13-minute half-life of endogenous amylin.
The molecular weight of Cagrilintide is approximately 4.4 kDa, and the lyophilized powder is typically provided as the acetate salt. For reconstitution in research protocols, Cagrilintide is soluble in aqueous buffers at near-physiological pH, though specific solubility parameters should be verified empirically under the conditions of the intended experiment. The fatty-acid conjugation renders the peptide amenable to subcutaneous administration in animal models, producing sustained plasma concentrations that facilitate once-weekly dosing regimens in chronic metabolic studies.
Importantly, Cagrilintide is an analog of amylin, not a GLP-1 receptor agonist, and it signals through a distinct receptor system. The amylin receptor complex is formed by the heterodimerization of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMPs 1, 2, or 3). Cagrilintide exhibits preferential affinity for the CTR/RAMP1 and CTR/RAMP3 complexes, which predominate in the area postrema and other hindbrain nuclei critical to appetite regulation. This receptor selectivity profile distinguishes cagrilintide pharmacologically from calcitonin and calcitonin gene-related peptide (CGRP), both of which also signal through CTR/RAMP complexes but with different RAMP preferences and downstream effects.
Mechanism of Action
The mechanism of action of Cagrilintide is mediated through potent and sustained activation of amylin receptors located primarily in the central nervous system, with the area postrema of the brainstem serving as the principal site of action for its appetite-suppressive effects. The area postrema is a circumventricular organ that lies outside the blood-brain barrier, allowing circulating peptides such as amylin and its analogs direct access to neuronal populations that integrate peripheral metabolic signals and relay them to higher-order feeding centers, including the nucleus of the solitary tract, the lateral parabrachial nucleus, and the hypothalamic arcuate nucleus.
At the molecular level, Cagrilintide binding to the CTR/RAMP complex activates intracellular G-protein-coupled signaling cascades, primarily through Gs-mediated stimulation of adenylyl cyclase and subsequent elevation of cyclic AMP (cAMP) levels. This signaling event triggers neuronal depolarization in amylin-responsive neurons of the area postrema, leading to the transduction of a satiety signal that reduces meal size and overall food intake without the development of compensatory hyperphagia between meals — a hallmark of amylinergic appetite regulation that distinguishes it from certain other anorectic pathways.
Beyond its central effects on food intake, Cagrilintide recapitulates the peripheral actions of endogenous amylin, including dose-dependent slowing of gastric emptying. This gastroinhibitory effect is mediated through vagal afferent signaling and contributes to the postprandial regulation of nutrient absorption, thereby modulating the rate at which glucose and lipids enter the systemic circulation. In preclinical models, Cagrilintide has been shown to suppress postprandial glucagon secretion — an effect that is particularly relevant in the context of dysregulated glucagon output observed in type 2 diabetes. Unlike native amylin, which requires multiple daily injections due to rapid renal clearance and proteolytic degradation, the albumin-binding properties of Cagrilintide maintain tonic amylin receptor engagement over extended periods, enabling sustained modulation of these physiological processes.
An emerging area of investigation concerns the potential synergistic interactions between amylin receptor agonism and GLP-1 receptor activation. Both amylin and GLP-1 are secreted in response to nutrient ingestion and converge on overlapping but distinct neural circuits governing energy balance. Preclinical co-administration studies suggest that simultaneous engagement of these two receptor systems may produce additive or even synergistic effects on body weight reduction and glycemic control, prompting investigation into fixed-ratio combination formulations for metabolic disease research.
Research Applications
Cagrilintide serves as a versatile research tool across multiple domains of metabolic and neuroendocrine investigation. The following applications represent the most active areas of current preclinical inquiry:
Obesity and Energy Homeostasis Research: Cagrilintide is extensively employed in diet-induced obesity (DIO) rodent models to investigate the mechanisms by which sustained amylin receptor activation modulates food intake, body weight, and adiposity. Researchers utilize the compound to dissect the neural circuits mediating amylin-induced satiety, often in combination with conditional genetic approaches that selectively ablate amylin receptor components in discrete neuronal populations. Dose-response studies with Cagrilintide in DIO rats have demonstrated reductions in food intake of 30-50% and body weight loss of 10-15% over multi-week treatment periods, providing a benchmark for comparative evaluation of novel amylin analogs.
Diabetes and Glucose Metabolism: The glucagonostatic properties of Cagrilintide make it a compound of interest in models of type 2 diabetes. Investigators administer Cagrilintide to diabetic rodent models (e.g., ZDF rats, db/db mice) to evaluate its effects on postprandial glucose excursions, insulin sensitivity, and beta-cell function. Of particular interest is the potential for amylin agonism to complement incretin-based therapies, given that endogenous amylin and GLP-1 exhibit complementary effects on glucagon suppression and gastric emptying.
Gastric Motility Studies: The profound effect of Cagrilintide on gastric emptying rate makes it useful for studies of gastrointestinal transit and nutrient absorption kinetics. Researchers employ acetaminophen absorption tests, scintigraphy, or direct measurement of gastric contents in rodent models to quantify the dose-dependent delays in gastric emptying produced by Cagrilintide and to explore the vagal afferent signaling pathways that mediate this response.
Combination Therapy Research: A growing body of research investigates Cagrilintide in combination with GLP-1 receptor agonists (such as semaglutide) to evaluate potential additive or synergistic effects on metabolic endpoints. These studies are central to the preclinical rationale for dual amylin/GLP-1 receptor agonism as a strategy for obesity and diabetes intervention.
Amylin Receptor Pharmacology: As a high-affinity, long-acting amylin receptor agonist, Cagrilintide serves as a reference ligand for competitive binding assays, calcium mobilization assays, and cAMP accumulation assays designed to characterize novel amylin receptor modulators. Its albumin-binding properties also make it a useful tool for studying the pharmacokinetic-pharmacodynamic relationships of lipidated peptide therapeutics.
Key Research Studies
The scientific foundation for Cagrilintide research rests on a substantial body of preclinical and clinical literature spanning amylin biology, amylin receptor pharmacology, and the development of long-acting amylin analogs.
Lau and colleagues (2021) conducted a pivotal phase 2, dose-finding clinical trial evaluating once-weekly subcutaneous Cagrilintide in individuals with overweight or obesity. The trial demonstrated dose-dependent reductions in body weight of up to 10.8% over 26 weeks, with gastrointestinal adverse events representing the most common side effect profile (PMID 34555158). This study established Cagrilintide as the first long-acting amylin analog to demonstrate clinically meaningful weight loss with once-weekly dosing, catalyzing expanded investigation into the amylin signaling axis for obesity pharmacotherapy.
The molecular pharmacology of amylin receptors has been comprehensively reviewed by Hay and colleagues (2015), who detailed the structure-function relationships governing CTR/RAMP complex formation, ligand selectivity, and downstream signaling. This review remains a foundational reference for investigators designing amylin receptor binding and activation assays (PMID 27788214).
Lutz (2008) provided a landmark review of the role of amylin in the physiological control of energy homeostasis, synthesizing evidence from genetic ablation studies, pharmacological intervention studies, and neuroanatomical tracing experiments. The review articulated the concept of amylin as a meal-ending satiety signal and delineated the brainstem-to-hypothalamic circuitry through which amylin exerts its effects on feeding behavior (PMID 18463238).
The pharmacology and physiology of amylin as a pancreatic and neuroendocrine hormone were systematically described by Young (2005), encompassing the discovery of amylin, its co-secretion with insulin, its metabolic effects, and the development of amylinomimetic peptides. This work contextualized the therapeutic rationale for targeting the amylin receptor system in metabolic disease (PMID 16290731).
Lutz (2011) further expanded on the amylinergic control of food intake, detailing the convergence of amylin signaling with other anorectic pathways including leptin, cholecystokinin (CCK), and GLP-1. The review highlighted the non-redundant nature of amylin-mediated satiety and its potential as a target for combination pharmacotherapy (PMID 21871851).
Handling and Storage
Proper handling and storage of Cagrilintide are essential to maintain the structural integrity and biological activity of the peptide throughout the duration of the research protocol. Upon receipt, lyophilized Cagrilintide should be stored at -20°C or -80°C in a desiccated environment, protected from light and moisture. Under these conditions, the lyophilized peptide is stable for the duration indicated on the certificate of analysis, typically 12-24 months from the date of manufacture.
Reconstitution should be performed using sterile, high-purity aqueous buffer appropriate to the experimental system. Bacteriostatic water (0.9% benzyl alcohol), sterile phosphate-buffered saline (PBS), or sterile 0.9% sodium chloride are commonly employed. The choice of reconstitution medium should be guided by the intended route of administration in animal studies and compatibility with downstream analytical methods. Gentle agitation or rolling — rather than vortexing — is recommended to dissolve the lyophilized cake, as excessive mechanical stress can induce aggregation or precipitation of the peptide.
Following reconstitution, Cagrilintide solutions should be aliquoted into single-use volumes to minimize freeze-thaw cycling, which is detrimental to peptide stability. Reconstituted aliquots may be stored at -20°C or -80°C for short-term use (typically up to 30 days), though researchers should validate stability under their specific storage conditions. For longer-term storage, lyophilized aliquots should be prepared by flash-freezing in liquid nitrogen followed by lyophilization. Avoid storage of reconstituted peptide at 4°C for extended periods, as gradual degradation, oxidation, and microbial contamination may occur.
As with all research peptides, aseptic technique should be employed during reconstitution and handling. Filter sterilization (0.22 µm) of reconstituted solutions is recommended prior to in vivo administration to minimize the risk of introducing microbial contaminants into experimental subjects.
Safety and Precautionary Information
Cagrilintide is classified as a research chemical and should be handled exclusively by qualified laboratory personnel trained in the safe handling of peptide compounds. Appropriate personal protective equipment (PPE) — including nitrile or latex gloves, a laboratory coat, and safety glasses — should be worn at all times when handling the lyophilized powder or reconstituted solutions. All work should be conducted in a properly ventilated laboratory environment, preferably within a certified chemical fume hood or biosafety cabinet when manipulating the dry powder.
Inhalation of lyophilized peptide powder, ingestion, skin contact, and eye contact must be strictly avoided. In the event of accidental exposure, affected areas should be flushed thoroughly with water for at least 15 minutes, and medical attention should be sought if irritation persists. A Safety Data Sheet (SDS), if available from the manufacturer, should be reviewed in advance of all experimental procedures. Researchers are responsible for understanding the potential risks associated with peptide compounds and for implementing appropriate risk mitigation strategies within their laboratory.
Cagrilintide has not been evaluated by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory agency for safety or efficacy in humans. It is supplied solely as a research reagent, and any deviation from this intended use is the sole responsibility of the end user. Disposal of unused or expired Cagrilintide should comply with all applicable institutional, local, state, and federal regulations governing the disposal of chemical and biological waste.
Frequently Asked Questions
Q: What is the recommended reconstitution protocol for Cagrilintide in rodent studies?
A: For subcutaneous administration in rodent models, Cagrilintide is typically reconstituted in sterile phosphate-buffered saline (PBS, pH 7.4) or sterile 0.9% sodium chloride to a final concentration appropriate for the target dose. The lyophilized cake should be dissolved with gentle agitation, not vortexing. Following reconstitution, filtration through a 0.22 µm sterile filter is recommended. Researchers should determine the optimal vehicle and concentration through pilot solubility and tolerability studies in their specific model system.
Q: How does Cagrilintide differ from pramlintide?
A: Both Cagrilintide and pramlintide are amylin receptor agonists, but they differ fundamentally in their pharmacokinetic profiles. Pramlintide (marketed as Symlin) has a half-life of approximately 45-50 minutes in humans and requires multiple daily injections before meals. Cagrilintide, by contrast, incorporates a fatty-acid albumin-binding moiety that extends its half-life to approximately 7-8 days, enabling once-weekly administration in research protocols. Additionally, Cagrilintide has been engineered with amino acid substitutions distinct from those in pramlintide to further reduce amyloidogenic potential and optimize receptor selectivity.
Q: Can Cagrilintide and GLP-1 receptor agonists be co-administered in preclinical studies?
A: Yes, co-administration of Cagrilintide with GLP-1 receptor agonists such as semaglutide or liraglutide is an active area of preclinical investigation. Studies suggest that simultaneous activation of amylin and GLP-1 receptors produces additive or synergistic effects on food intake and body weight reduction, potentially through complementary actions on distinct neural populations in the brainstem and hypothalamus. Researchers conducting co-administration studies should carefully consider dosing schedules, as both compounds influence gastric emptying and may produce compounded gastrointestinal effects.
Q: What species are appropriate for Cagrilintide research?
A: Cagrilintide has been studied most extensively in rodent models (rats and mice), which are the standard preclinical species for metabolic research. The amylin receptor system is highly conserved across mammals, though species-specific differences in receptor pharmacology and metabolic rate should be considered when translating dosing regimens. Non-human primate data for Cagrilintide are limited in the published literature. Researchers should validate target engagement and pharmacokinetic parameters in their chosen model species.
Q: What analytical methods are available to verify reconstituted Cagrilintide identity and purity?
A: The identity and purity of reconstituted Cagrilintide can be verified using high-performance liquid chromatography (HPLC), typically reversed-phase HPLC with UV detection at 214 or 220 nm. Mass spectrometry (ESI-MS or MALDI-TOF) provides confirmation of molecular weight and can detect oxidative modifications or degradation products. Amino acid analysis may be employed for precise quantitation of peptide content. Peptide content, as opposed to gross weight, should be used for accurate dosing calculations, as the lyophilized powder typically contains residual water and counterions that contribute to total mass.
References
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management: a randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10306):1065-1076. doi:10.1016/S0140-6736(21)01751-7. PMID: 34555158.
- Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides. Pharmacol Rev. 2015;67(3):564-600. doi:10.1124/pr.114.010009. PMID: 27788214.
- Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1475-R1484. doi:10.1152/ajpregu.00703.2009. PMID: 18463238.
- Young A. Amylin: physiology and pharmacology. Adv Pharmacol. 2005;52:2-50. doi:10.1016/S1054-3589(05)52002-7. PMID: 16290731.
- Lutz TA. Amylinergic control of food intake. Physiol Behav. 2011;105(1):78-82. doi:10.1016/j.physbeh.2011.03.016. PMID: 21871851.
Reviews
There are no reviews yet.